Related by context. All words. (Click for frequent words.) 78 multivariate analyzes 78 multivariable analysis 77 univariate 76 univariate analyzes 75 multivariate analysis 74 multivariate Cox 72 multivariate logistic regression 71 covariates 71 P = .# 71 confidence intervals CIs 71 covariate 71 Kaplan Meier analysis 71 Univariate analysis 70 posttreatment 70 logistic regression analysis 70 preoperative PSA 70 Multivariate analysis 70 logistic regression model 70 pT3 69 multivariate adjustment 69 % CI #.#-#.# [007] 69 p = .# [002] 69 % CI #.#-#.# [006] 69 % CI #.#-#.# [003] 69 biochemical recurrence 68 nonfatal MI 68 bivariate 68 lymph node metastasis 68 multiple logistic regression 68 HOMA IR 68 postintervention 68 multivariable Cox 68 MMSE score 68 multivariable logistic regression 68 logistic regression analyzes 68 rs# [004] 68 PCa 68 SLNB 68 lymphovascular invasion 68 serum PSA 68 Subgroup analysis 67 Univariate 67 ANOVA 67 CR nPR 67 % CI #.#-#.# [002] 67 pCR 67 p = #.# [002] 67 confidence interval CI 67 logistic regression models 67 confidence interval #.#-#.# 67 pT2 67 logistic regression 67 nondiabetic patients 67 TT genotype 66 Kaplan Meier method 66 advanced adenoma 66 serum concentrations 66 biochemical relapse 66 p = #.# [003] 66 CC genotype 66 distant metastasis 66 multivariable adjusted 66 CVD mortality 66 % CI #.#-#.# [008] 66 familial aggregation 66 definite stent thrombosis 66 bivariate analysis 66 multivariable analyzes 66 prostate cancer CaP 66 serum creatinine levels 66 seropositivity 66 tertiles 66 mL/min/#.# m 2 66 locoregional recurrence 66 immunostaining 66 tHcy 66 prospectively defined 66 μmol L 66 creatinine ratio 66 tertile 65 HER2 expression 65 clinicopathological features 65 F FDG PET 65 advanced neoplasia 65 Kaplan Meier survival 65 endometrial thickness 65 advanced adenomas 65 UGT#A# * 65 periprocedural 65 % Confidence Interval 65 MDRD 65 seminal vesicle invasion 65 histologic 65 histological subtype 65 histologic subtype 65 interobserver reliability 65 nonsignificant 65 invasive carcinomas 65 highest tertile 65 comorbidity 65 serum estradiol 65 intact parathyroid hormone 65 lowest tertile 65 androgen suppression 65 Logistic regression 65 elevated LDH 64 MetS 64 HBeAg 64 Subgroup analyzes 64 CIN2 + 64 specific antigen PSA 64 lactate dehydrogenase 64 posttransplant 64 neoadjuvant chemotherapy 64 cTnI 64 RRM1 64 IPAH 64 homozygotes 64 colorectal adenoma 64 alanine aminotransferase ALT 64 bone scintigraphy 64 PSADT 64 thyroglobulin 64 biopsy Gleason 64 HbA 1c levels 64 Logistic regression analysis 64 intraobserver 64 IL#B 64 radical prostatectomy RP 64 Multivariate analyzes 64 hsCRP levels 64 -#.# ± [002] 64 pg ml 64 Kaplan Meier 64 hormone receptor negative 64 HER2 amplification 64 femoral neck BMD 64 lymph node involvement 64 kidney allograft 64 heterozygotes 64 perioperative complications 64 fasting insulin 64 SUVmax 64 nodal metastases 64 conditional logistic regression 64 elevated ALT 64 mRNA expression 64 HRCT 64 lymphocyte count 64 subscale scores 64 undetectable HBV DNA 64 histopathological 64 bivariate analyzes 63 sociodemographic characteristics 63 liver histology 63 TIMP 1 63 lymphocytosis 63 Bonferroni correction 63 antibody titer 63 BRCA2 mutation carriers 63 nonobese 63 serum prostate 63 hip BMD 63 distant metastases 63 NMIBC 63 prognostic factors 63 NIHSS score 63 regression coefficient 63 platelet reactivity 63 generalized estimating 63 genotypic resistance 63 breast carcinoma 63 chi squared 63 eplerenone 63 clinicopathological 63 lymph node metastases 63 ertapenem 63 nonparametric 63 lumbar spine BMD 63 plasma cortisol 63 hematologic toxicity 63 extracapsular extension 63 carotid IMT 63 subgroup analyzes 63 β blockers 63 endometrial carcinoma 63 glomerular filtration rate 63 SNP rs# [002] 63 immunohistochemical analysis 63 pretransplant 63 tPSA 63 parous women 63 Kaplan Meier curves 63 preintervention 63 preoperative 63 Doxil ® 63 rs# [002] 63 LV dysfunction 63 thyrotropin levels 63 nephrectomy 63 inhibin B 63 serum testosterone 63 postoperative chemotherapy 63 immunoreactivity 63 D dimer 63 cytologic 63 HSCT 63 serum albumin 63 response pCR 63 p = 63 MADRS score 63 Montgomery Åsberg Depression 63 EBRT 63 proportional hazards 63 intima media thickness 62 lymphadenectomy 62 aspartate aminotransferase AST 62 CI #.#-#.# [002] 62 progression TTP 62 β = 62 coronary calcification 62 K ras mutations 62 BMI z 62 comorbidities 62 microvessel density 62 baseline LDH 62 prognostic factor 62 rheumatoid factor 62 rs# [001] 62 nodal metastasis 62 adenoma recurrence 62 statistical significance p 62 Pearson correlation coefficient 62 depressive symptomatology 62 â ‰ ¥ 62 % CI #.#-#.# [001] 62 PSA nadir 62 alanine aminotransferase 62 isoprostane 62 postoperative complication 62 odds ratios ORs 62 symptomatic VTE 62 HbA 1c 62 dehydroepiandrosterone sulfate 62 esophageal carcinoma 62 carotid intima media 62 LV ejection fraction 62 lobular carcinoma 62 HIV RNA 62 locoregional 62 TP# mutations 62 Hazard Ratio HR 62 psychiatric comorbidity 62 CHD mortality 62 mg kg dose 62 HBeAg negative patients 62 rs# [003] 62 DRD2 62 immunohistochemical staining 62 SCr 62 ABCB1 62 macroalbuminuria 62 TIMP 62 median PFS 62 NIHSS 62 FEV ^ sub 62 virological response 62 ± SD 62 CI #.#-#.# [001] 62 ≥ 62 PSA kinetics 62 KRAS mutations 62 multivariate regression analysis 62 atypical hyperplasia 62 gene polymorphisms 62 nonvertebral fractures 62 linear regression analyzes 62 coronary stenosis 62 Histologic 62 invasive ductal 62 secondary efficacy endpoint 62 coinfected patients 62 sd = 62 tumor histology 62 radical nephrectomy 62 mg BID dose 62 neutrophil counts 62 adiponectin concentrations 62 symptomatic intracerebral hemorrhage 62 Kruskal Wallis test 62 leukocyte count 62 Main Outcome Measure 62 histopathologic 62 neutrophil count 62 virologic failure 62 NNRTI resistance 62 bronchoalveolar lavage 62 Ki# 62 AST ALT 62 HBeAg seroconversion 62 virologic response 62 transferrin saturation 61 axillary lymph node 61 = #.#-#.# 61 postoperative mortality 61 DAS# [002] 61 colorectal neoplasia 61 proband 61 recurrent venous thromboembolism 61 immunohistochemical 61 OGTT 61 interquartile range 61 nmol 61 mammographic density 61 ß = 61 regression analyzes 61 CI -#.# 61 Poisson regression 61 vertebral fracture 61 interobserver 61 hormone receptor status 61 prostate carcinoma 61 elevated troponin 61 umol L 61 sociodemographic factors 61 NHANES III 61 prognostic significance 61 polyp recurrence 61 histologically confirmed 61 baseline CD4 61 Plasma concentrations 61 scintigraphic 61 clinico pathological 61 APOE genotype 61 serum cortisol 61 lymphopenia 61 μg liter 61 % CI #.#-#.# [005] 61 ultrasonographic 61 differentially expressed genes 61 alkaline phosphatase ALP 61 Secondary efficacy endpoints 61 liver metastasis 61 obstructive coronary artery 61 noncarriers 61 VcMP 61 CaP 61 p = #.# [004] 61 interrater reliability 61 allele frequencies 61 lupus anticoagulant 61 p = NS 61 PSQI 61 urine cytology 61 DAS# scores 61 BRCA1 mutation carriers 61 ADRB2 61 DAS# remission 61 statistically significant p = 61 imatinib therapy 61 MACCE 61 FDG uptake 61 cystatin C 61 HGPIN 61 Kaplan Meier estimates 61 laboratory abnormalities 61 Histological 61 mucinous 61 achieved CCyR 61 Brief Psychiatric 61 estimated GFR 61 pelvic lymphadenectomy 61 TEAEs 61 CCyR 61 binary restenosis 61 liver transplant recipients 61 hemoglobin Hb 61 aspartate aminotransferase 61 serum homocysteine 61 probands 61 histologically proven 61 apolipoprotein B 61 baseline FEV 61 Preoperative 61 Rating Scale BPRS 61 TOP2A 61 CR CRu 61 methotrexate monotherapy 61 micrometastasis 61 REYATAZ r arm 61 doxorubicin docetaxel 61 IPSS 61 urinary calcium 61 sensitivity specificity 60 QIDS SR 60 MMSE scores 60 Secondary endpoints 60 adrenalectomy 60 serum CRP 60 subscales 60 μg ml 60 TURBT 60 Regression analyzes 60 hydroxyvitamin D levels 60 Main Outcome Measures 60 comorbid conditions 60 uM 60 underwent resection 60 D Dimer 60 estimated glomerular filtration 60 covariance ANCOVA 60 Stent thrombosis 60 endoscopic remission 60 nonresponders 60 Wilcoxon rank sum 60 estrogen receptor ER 60 T1c 60 myocardial viability 60 postoperative morbidity 60 hepatocellular carcinomas 60 serum IGF 60 CYP#D# genotype 60 Preoperatively 60 euthyroid 60 hydronephrosis 60 Postoperative complications 60 log# copies mL 60 albumin excretion rate 60 CI = 60 ALT elevation 60 baseline HbA1c 60 DAS# CRP 60 renal cell carcinomas 60 APACHE II 60 achieved statistical significance 60 pneumonectomy 60 microsatellite instability 60 radiotherapy RT 60 adjuvant radiotherapy 60 ^ sup #m 60 contralateral breast cancer 60 ovarian carcinoma 60 nonmetastatic 60 Supplementary Table 60 % CI #.#-#.# [004] 60 flutamide 60 MLH1 60 MGUS 60 genotypic 60 relapsed MM 60 glycosylated hemoglobin HbA1c 60 subscore 60 fasting plasma 60 spirometric 60 metabolic parameters 60 troponin T 60 Kaplan Meier curve 60 nmol L 60 APOE e4 60 transrectal ultrasound guided 60 neoadjuvant 60 creatinine levels 60 T2DM 60 glycated hemoglobin levels 60 SNP rs# [001] 60 affective psychosis 60 serum ALT 60 ANCOVA 60 iodixanol 60 cytoreductive nephrectomy 60 node metastases 60 gastric adenocarcinoma 60 neoadjuvant therapy 60 #OHD 60 bladder carcinoma 60 ischemic lesions 60 normal karyotype 60 rebleeding 60 urodynamic 60 p = .# [001] 60 HbA1C levels 60 HDRS 60 parasitaemia 60 incomplete revascularization 60 AUCs 60 C#BL/#J mice 60 thyroid carcinoma 60 ALT flares 60 serum HCV RNA 60 HepG2 cells 60 Multivariate logistic regression 60 mRS 60 multivariable adjustment 60 invasive lobular 60 morphometric vertebral fractures 60 chi ^ sup 60 potential confounders 60 NGAL 60 EDSS score 60 histopathologic examination 60 pathologic 60 ASCUS 60 cardiac troponin T 60 regression coefficients 60 T1a 60 nonfasting triglyceride levels 60 SGRQ 60 protein excretion 60 ADCS ADL 60 axillary node 60 serum ferritin 60 Index CDAI 60 #.#ng/ml 60 ipsilateral stroke 60 cTnT 60 multiple linear regression 60 HRQoL 60 plasma pharmacokinetics 60 KRAS mutation 60 confounders 60 urothelial carcinoma 60 sleeve lobectomy 59 P ≤ 59 K#R [002] 59 SGPT 59 serum GGT 59 gastrectomy 59 carotid stenosis 59 unpaired t 59 receiving VICTRELIS 59 serum leptin 59 underwent surgical resection 59 oncologic outcomes 59 haematologic 59 tipranavir r 59 gene polymorphism 59 FDG-PET/CT 59 stepwise logistic regression 59 erythrocyte sedimentation rate 59 pancreatic adenocarcinoma 59 perioperative mortality 59 dose dependently 59 prior chemotherapy regimens 59 nmol liter 59 F FDG uptake 59 sociodemographic variables 59 statistically significant 59 Immunohistochemical staining 59 antiretroviral naïve 59 radiographic progression 59 statistically significant correlations 59 serum lactate 59 Inhibin B 59 serum HBV DNA 59 eosinophil count 59 Primary endpoints 59 pmol L 59 rho = 59 CD4 CD8 59 #F FDG PET 59 patients evaluable 59 EQ 5D 59 inotropic 59 glomerular filtration 59 intravesical therapy 59 HER2 overexpression 59 Flu Cy 59 microalbuminuria 59 graft occlusion 59 bronchioloalveolar carcinoma 59 CsA 59 eGFR 59 airway responsiveness 59 prognostic variables 59 Response Evaluation Criteria 59 COMT genotype 59 nonpregnant women 59 WOMAC scores 59 complete cytogenetic response 59 nonfatal myocardial infarction 59 Serum creatinine 59 Insulin sensitivity 59 inversely associated 59 carcinoembryonic antigen 59 leukopenia 59 LPS induced 59 abdominal adiposity 59 GSTP1 59 cytokeratin 59 inhibin 59 unfavorable prognostic 59 variant alleles 59 extensive metabolizers 59 radical cystectomy 59 meta regression 59 correlation coefficients 59 Operative mortality 59 glycosylated hemoglobin 59 fosamprenavir 59 metabolite concentrations 59 statistically nonsignificant 59 reinfarction 59 curative resection 59 recurrent VTE 59 hyperintensity 59 serum PTH 59 Multiple logistic regression 59 ECG abnormalities 59 Postoperative 59 Crohn Disease Activity 59 echocardiographic parameters 59 LVEF 59 psychiatric comorbidities 59 serum urate levels 59 PCWP 59 mutated KRAS 59 SLN biopsy 59 contralateral breast 59 CIN3 59 adenoma 59 noncardiac 59 autonomic dysfunction 59 malignant lesions 59 extramedullary 59 FOLFOX4 59 adenoma detection 59 androgen deprivation 59 mIU ml 59 hydroxyvitamin D concentrations 59 postoperative radiotherapy 59 preoperative chemotherapy 59 PASI scores 59 urine albumin 59 antigen PSA levels 59 cystectomy 59 prospectively stratified 59 homocysteine concentrations 59 serum folate 59 serum triglycerides 59 lignan intake 59 progesterone receptor negative 59 #β estradiol 59 adjuvant tamoxifen 59 p# antigen 59 Recurrence Score 59 variance ANOVA 59 dose dexamethasone 59 WOMAC pain 59 TMPRSS2 ERG fusion 59 mU liter 59 Secondary endpoints included 59 ROC curves 59 plasma leptin 59 squamous histology 59 sonographic findings 59 QTc prolongation 59 invasive carcinoma 59 ECOG PS 59 semiquantitative 59 bioavailable testosterone 59 pretest probability 59 timepoints 59 NYHA functional class 59 metaplasia 59 clinicopathologic 59 urinary excretion 59 completely resected 59 nomogram 59 CORE OM 59 rCBF 59 colorectal neoplasms 59 chest radiographs 59 FOLPI 59 dimensional echocardiography 59 multivariate adjusted 59 calculated creatinine clearance 59 Common Toxicity Criteria 59 serum biomarker 59 Partial Responses 59 seronegative 59 pamidronate 59 5 HTTLPR 59 visceral metastases 59 angiographically 59 salpingo oophorectomy 59 subclinical atherosclerosis 59 renal cysts 59 histopathologic diagnosis 59 transvaginal sonography 59 postoperative complications 59 Immunohistochemical analysis 59 serum creatinine 59 mg/m2 dose 59 rFSH 59 PaO 2 59 #ng/ml 59 leukocytosis 59 radioiodine therapy 59 pg mL 59 perineural invasion 59 APTIVUS r 59 TACE 59 tumor necrosis 59 nmol L. 59 oral glucose tolerance 59 Pearson correlation coefficients 59 mesalamine granules 59 serum calcium levels 58 serum phosphate 58 thiopurine 58 ADAS Cog 58 ERalpha 58 #mg BID [003] 58 ERCC1 58 virological failure 58 5-FU/LV 58 SE alleles 58 Multivariate analysis showed 58 thymoma 58 CANCIDAS 58 variant rs# 58 perioperatively 58 evaluable 58 normotensive 58 mIU L 58 preoperatively 58 methacholine challenge 58 hypogonadal 58 HIV uninfected 58 extracolonic findings 58 BRCA2 carriers 58 binary logistic regression 58 atheroma volume 58 airway hyperresponsiveness 58 #q# deletion syndrome 58 transaminase elevations 58 ERBB2 58 5-fluorouracil/leucovorin 58 DLTs 58 splenic 58 T2 lesions 58 tirofiban 58 beta carotene supplementation 58 histologically 58 HLA DRB1 * 58 CYP#D# inhibitor 58 lopinavir r arm 58 subtrochanteric 58 posttest 58 statistically significant p 58 revascularizations 58 Oncotype DX Recurrence Score 58 hip resurfacing arthroplasty 58 fructosamine 58 hepatic enzyme 58 aminotransferase levels 58 HNSCC 58 albumin excretion 58 ALND 58 neoplasias 58 promoter methylation 58 neurologic complications 58 Ishak fibrosis score 58 micafungin 58 ADAS cog 58 statistically significant correlation 58 DMARD 58 neutropaenia 58 underwent CABG 58 MIC# [001] 58 elevated transaminases 58 severe neutropenia 58 aminotransferase 58 perioperative morbidity 58 AUC0 58 caspofungin 58 Hb A1C 58 neurodevelopmental impairment 58 NT proBNP 58 Doppler sonography 58 microalbumin 58 ‰ ¥ 58 S aureus 58 troponins 58 anti HBs 58 desvenlafaxine succinate 58 neurocognitive function 58 pre eclamptic 58 glucuronide 58 Charlson comorbidity index 58 adenomatous polyps 58 cranial irradiation 58 concomitant medications 58 Cronbach alpha 58 STRIDE PD 58 Lp PLA 2 58 crossclamp 58 plain radiographs 58 explanatory variables 58 Median PFS 58 #F FDG 58 primary aldosteronism 58 T#I [002] 58 atazanavir ritonavir 58 lactate dehydrogenase LDH 58 RYGB 58 aminotransferases 58 NNT = 58 arterial thickening 58 Cystatin C 58 underwent radical prostatectomy 58 serum calcium 58 plasma folate 58 proteinuria 58 OPCAB 58 cystatin 58 carotid artery intima media 58 Bonferroni 58 chemoradiation therapy 58 arterial thromboembolic events 58 de novo AML 58 alexithymia 58 cytogenic 58 extrapyramidal symptoms 58 operable breast cancer 58 APOC3 58 inducible nitric oxide synthase 58 hepatic fibrosis 58 Gram stain 58 arterial oxygen saturation 58 doxorubicin cyclophosphamide 58 strongest predictor 58 hepatic enzymes 58 HIV HCV coinfected 58 placebo fluoxetine 58 Baseline characteristics 58 PTPN# 58 Lymph node 58 metastatic lymph nodes 58 graft dysfunction 58 PREZISTA r arm 58 nonalcoholic steatohepatitis NASH 58 maternal serum 58 resected pancreatic cancer 58 clinically meaningful improvement 58 nephrogenic 58 chemoradiotherapy 58 prostate cancer PCa 58 IGFBP 58 tipranavir ritonavir 58 remission CR 58 chlorambucil 58 serum urate 58 clinically localized prostate 58 CLL SLL 58 leucopenia 58 serum uric acid 58 reflux esophagitis 58 adjuvant therapies 58 nonadherence 58 luminal 58 CTEPH 58 HRQL 58 κ 58 FDG PET 58 TNF blocker therapy 58 periprocedural MI 58 Alkaline Phosphatase 58 neurologic progression 58 μg L 58 GSTM1 58 clodronate 58 hallux valgus 58 interobserver agreement 58 transabdominal 58 Genotypic 58 secondary efficacy endpoints 58 serous ovarian cancer 58 abnormal p# biomarker 58 cerebral microbleeds 58 Visual Analogue Scale VAS 58 carotid artery thickness 58 left ventricular systolic 58 Hazard Ratio 58 plasma lipid 58 CD# expression [002] 58 allelic 58 abnormal cytology 58 MIRP 58 umbilical artery 58 clomipramine 58 transthoracic echocardiography 58 mITT population 58 UACR 58 HRQOL 58 retrospective cohort 58 HAQ DI 58 creatinine clearance 58 colorectal carcinoma 58 epithelial ovarian cancer 58 urinary albumin 58 TNFalpha 58 GG genotype 58 reach statistical significance 58 liver biopsies 58 #Gy 58 nephron sparing surgery 58 HBeAg positive patients 58 lymphocyte counts 58 variant allele 58 HBsAg 58 sarcomatoid 58 elevated creatinine 58 Multivariate analysis revealed 58 nonoperative treatment 58 contralateral 58 oblimersen 58 biopsied breast 58 isoenzyme 58 resected tumors 58 prespecified secondary 58 normoxic 58 nonsignificant difference 58 nonobese patients 58 fractional anisotropy 58 KRAS status 58 composite endpoint 58 prevalences 58 undergone radical prostatectomy 58 microg 58 interleukin IL -6 58 adjuvant chemotherapy 58 Cytogenetic 58 independent prognostic marker 58 HbA1c levels 58 squamous intraepithelial lesions 58 hypophosphatemia 58 pharmacokinetics PK 58 Comorbidity 58 neoplastic 58 aortic atherosclerosis 58 Secondary endpoints include 58 μg dL 58 beta blocker therapy 58 antithymocyte globulin 58 situ LCIS 58 TRUS 58 postdischarge 58 prespecified 58 serum TSH 58 hepatorenal syndrome 58 depressive symptom 58 cellularity 58 FDG PET imaging 58 laterality 58 gadolinium enhanced 58 undetectable PSA 58 adnexal mass 58 allele frequency 58 undergoing radical cystectomy 58 myocardial necrosis 58 mycophenolate mofetil 58 hypovitaminosis D 58 Disease Activity 58 psychosocial variables 57 RECIST criteria 57 thrombocytopenic 57 median CD4 57 multivariable 57 ng dL 57 detrusor overactivity 57 antiphospholipid antibodies 57 systolic dysfunction 57 pathologic examination 57 MDRD equation 57 XIENCE V PROMUS Stent 57 osteopenic 57 femoral neck fracture 57 Western blotting 57 statistically significant differences 57 logistic regressions 57 CrCl 57 orthotopic 57 pathologic diagnosis 57 fetuin 57 differentially expressed 57 mutated K ras 57 histological 57 mU L 57 plasma lipids 57 hemorrhagic complications 57 serum thyroglobulin 57 creatine kinase 57 parenchymal 57 cytogenetic abnormalities 57 dapagliflozin plus 57 androgen ablation 57 postprocedure 57 intraclass correlation coefficients